Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Perusinghe

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Development (Cambridge, England)|September 1, 1995
HGF/SF: a potent cytokine for mammary growth, morphogenesis and developmentB Niranjan, L Buluwela, J Yant, et al.
Oncogene|January 11, 2007
Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1K M Sutton, S Hayat, N-M Chau, et al.
British Journal of Cancer|July 20, 2000
Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2E A Rapley, R Barfoot, C Bonaïti-Pellié, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Development (Cambridge, England)|September 1, 1995
HGF/SF: a potent cytokine for mammary growth, morphogenesis and developmentB Niranjan, L Buluwela, J Yant, et al.
Oncogene|January 11, 2007
Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1K M Sutton, S Hayat, N-M Chau, et al.
British Journal of Cancer|July 20, 2000
Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2E A Rapley, R Barfoot, C Bonaïti-Pellié, et al.
Pageof 2